Background. Daily peritoneal exposure to peritoneal dialysis fluid (PDF) induces severe morphological alterations including fibrosis and angiogenesis that lead to a loss of peritoneal ultrafiltration (UF) capacity. Since cyclooxygenase (COX)-2 is involved in fibrosis and angiogenesis, we investigated the in vivo effects of a selective COX-2 inhibitor (celecoxib) in a rat-PD model. Methods. Sixteen rats daily received 10 ml of conventional PDF for 4-5 weeks intraperitoneally. Half of them (n = 8) daily received celecoxib (20 mg/kg BW) via oral gavage, and the other half (n = 8) received vehicle via oral gavage. The study also included two control groups (no PDF instillations), each consisting of n = 8 animals that daily received celecoxib or vehicle, respectively, via oral gavage. Functional, morphological and cellular parameters were analysed. Results. PDF exposure induced an inflammatory condition evidenced by the increased leucocyte number and synthesis of MCP-1, VEGF and hyaluronic acid. After PDF exposure, the omentum showed intense angiogenesis and milky spots formation. Parietal peritoneum showed increased angiogenesis, lymphangiogenesis, submesothelial matrix thickness and enhanced expression of mesothelial aquaporin1 (Aqp1). Concomitant PDF and celecoxib exposure drastically reduced PGE2 levels, angiogenesis, lymphangiogenesis, fibrosis and milky spot formation in studied tissues, but did not modify mesothelial Aqp1 expression nor the tissue expression of VEGF and inflammatory markers. PDF exposure induced severe UF failure that celecoxib treatment completely prevented. Conclusions. Altogether, celecoxib treatment improves UF capacity and reduces morphological alterations in our rat PD model.
Introduction
During peritoneal dialysis (PD), the peritoneal membrane is used as a dialysing organ and constantly exposed to peritoneal dialysis fluid (PDF). The daily instillation of PDF creates an intraperitoneal nonphysiological environment that sustains the development of morphological changes. A chronically exposed peritoneal membrane is characterized by interstitial fibrosis, alteration in the mesothelial layer and new vessel formation, and altogether these events are thought to be the major culprits in determining ultrafiltration (UF) failure and PD withdrawal [1] . At the molecular level, there is increasing evidence that a number of cytokines, growth factors and prostaglandins play key roles in regulating and sustaining these processes [2] .
Cyclooxygenase (COX) enzymes catalyze the ratelimiting step in prostaglandin synthesis from arachidonic acid. Their metabolites play a pivotal role in multiple physiological and pathophysiologic processes. Specifically, COX-1 is constitutively expressed in most tissues and is responsible for maintaining physiological processes such as gastric and renal protection and platelet function. In contrast, COX-2 is induced in response to growth factors, cytokines and tumour promoters, and its expression has been demonstrated in immune and non-immune cells, both under inflammatory and proliferative conditions, and is dependent mostly on pro-inflammatory stimuli [3] .
Increased COX-2 expression is a key step to induce pathological angiogenesis (reviewed in [4] ) in many different tumours. COX-2 can stimulate angiogenesis via the production of the vascular endothelial growth factor (VEGF), a potent angiogenic growth factor, not only by increasing its mRNA transcription [5, 6] but also by the production of thromboxane A2, prostaglandin E2 (PGE2) and prostacycline, products of arachidonic acid that are direct stimulants of endothelial cells [7] [8] [9] . Furthermore, the effects of COX-2-induced prostanoids on angiogenesis are probably amplified via a feedback loop, because VEGF activates both phospholipase A2-mediated release of arachidonic acid and 3670 P. Fabbrini et al. COX-2 expression, thereby enhancing PGI2 and PGE2 production [10] .
Other evidence indicate that COX-2 can also induce fibrosis as shown by effective reduction of carbon tetrachloride-induced liver fibrosis in rats treated with a potent COX-2 inhibitor [11] . Furthermore, it has recently been shown [12] that TGF-β and collagen I production in human peritoneal cells exposed to PDF is mediated by the synthesis of PGE2, and that this process can be completely prevented by the use of a selective COX-2 inhibitor.
Whether COX-2 pathways are involved in PD-related angiogenesis or fibrosis is not known yet. In vitro experiments have demonstrated that under PD-like conditions, mesothelial and inflammatory cells and fibroblasts involved in peritoneal healing after abdominal surgery can express COX-2 [13] [14] [15] . A recent publication showed increased COX-2 expression in mesothelial cells that underwent epithelial to mesenchymal transition (EMT), although COX-2 inhibition did not prevent EMT. Moreover, in a mouse model of PD, COX-2 inhibition reduced fibrosis, but not angiogenesis and partially recovered ultrafiltration [16] .
Among the selective COX-2 inhibitors, celecoxib showed prevention of angiogenesis in several in vitro angiogenesis assays and in vivo cancer models [17] . Recent findings showed [18] that clinical and experimental effects of celecoxib may be wider than its COX-2 inhibitory capacity, opening new scenarios for its clinical use.
Therefore, the aim of our study was to investigate whether the morphological and functional alterations occurring in the peritoneal membrane after PDF exposure can be prevented through oral celecoxib treatment in our well-established chronic PD rat model.
Materials and methods

Animals
Male Wistar rats (Harlan CPB, Horst, The Netherlands) of the same age were used throughout the study. The animals were maintained under conventional laboratory conditions. The Animal Care Committee of the Vrije Universiteit of Amsterdam approved all animal experiments described and that were in accordance with the NIH guide for the care and use of laboratory animals.
Experimental design
A peritoneal catheter was implanted as previously described [19] . No omentectomy was performed, and rats had normal renal function. During a 1-week recovery period, the rats received daily 2 ml of saline solution containing 1 U/ml heparin, and on Day 8, daily instillation of 10 ml of standard PDF (Dianeal R PD4, 3.86% glucose, pH 5.2, Baxter R&D, Utrecht, The Netherlands) was started. Control animals (C) were not surgically treated and received no fluid instillation. Throughout the study, eight of the PDF-exposed and eight of the control animals received daily administration of celecoxib (20 mg/kg) [20] dissolved in polyethyleneglycol (PEG) via oral gavage. The other eight PDF-exposed and eight control animals received oral vehicle administration. After 4-5 weeks of PDF exposure, functional [90 min peritoneal equilibrium test (PET)] and morphological/cellular/immunological parameters were analysed. Evaluations of various parameters were done independently by two persons on coded material and the averages of both measurements were used. In this study, a total of eight animals in each group were evaluated.
PET test
At the end of the experimental period, a 90-min PET test was performed by injecting 30 ml of Dianeal 3.86% into the peritoneal cavity. After drainage, in each sample UF net volume was calculated and cell pellet collected, and the cell number and viability were determined in a haemocytometer on the basis of trypan blue exclusion. The cytocentrifuge preparations were stained with May-Grünwald Giemsa stain, and the cells were differentiated. Cell-free PET fluid was stored at −80 • C for determination of biomarkers and glucose absorption.
Part of the stored PET effluent was concentrated up to 30 times using a centrifugal filter device (Millipore Amicon R Ultra-4). In concentrated PET fluid we measured IL6 (NIBSC, South Mimms, UK) and VEGF (Quantikine R M, VEGF kit, R&D Systems, Inc., Minneapolis, USA) concentrations by an enzyme-linked immunosorbent assay, while in un-concentrated samples we determined hyaluronic acid (HA) (according to Fosang et al. [21] ), monocyte chemoattractant protein (MCP-1) (PharMingen, San Diego, CA, USA) and PGE2 (Quantikine R ,PGE2 kit, R&D Systems, Inc., USA).
Morphology
Tissue was dissected in a standardized fashion in order to obtain the same anatomical portion and to avoid mechanical trauma to mesothelial cells.
Omentum. Omental tissue was dissected and spread on glass slides for light microscopic examination. The whole mount preparations were stained with toluidine blue, and the number of blood vessels and the area of milky spots were counted as previously described [22] . The total milky spot surface of every individual omentum was calculated by multiplying the number of milky spots/cm 2 by the area per milky spot.
Parietal peritoneum. Cryostat sections (6 µm) were cut and stained using different antibodies to visualize blood vessels (CD31, PECAM, Serotec, Oxford,UK), Aquaporin1 (Aqp1) (a kind gift from Dr Peter Deen, Depatment of Physiology, UMC St Radboud, Nijmegen, The Netherlands), lymphatic vessels (Lyve 1, Cell Signaling Technology, Inc., The Netherlands), VEGF A (Calbiochem Darmstadt, Germany) and VEGF B (R&D systems, USA). The blood vessel number was counted and expressed per mm mesothelial length, while lymphatic vessels were quantified via a computer analysis (analySIS R pro, Olympus soft Imaging solutions GmbH) and expressed as percentage of tissue covered area. The same software was then used to measure the Aqp1 positive area at the mesothelial level in parietal peritoneum.
The thickness of the submesothelial extracellular matrix layer (ECM) was determined as the average of 10 independent measurements for each animal on Van Gieson stained sections.
Liver. Imprints of the mesothelial monolayer of the liver were obtained according to the method described by Whitaker et al. [23] and then stained according to May-Grünwald Giemsa. The changes in the mesothelial cell density were assessed by light microscopic analysis, using a scored eyepiece as previously described [19] .
Statistical analysis
All data were presented as median and range and have been analysed using the nonparametric Mann-Whitney U-test. Probability values of < 0.03 were considered significant, according to Bonferroni correction for multiple comparisons.
Results
Inhibition of COX-2 by celecoxib
PgE2 levels in cell-free PET fluids in PDF + celecoxib animals [33.1 pg/ml (0.6-90.3)] were significantly reduced compared to PDF-treated rats [79.3 pg/ml (49.3-142) P < 0.03] indicating effective COX-2 inhibition by celecoxib treatment. In the control group, PgE2 levels were as high as those in the PDF group (70.1 P > 0.3) indicating a sudden production of PgE2 after a single PDF exposure. In most C+celecoxib animals, PgE2 was below the detection limits (7 pg/ml) indicating a suppression of PgE2 production by celecoxib treatment. PDF, peritoneal dialysis fluids. a All data are expressed as the median (and range). b P < 0.01 versus C and C + celecoxib. c P < 0.03 PDF + celecoxib versus PDF.
Functional parameters
The PET in control animals resulted in 9.6 ml (9.0-10.8 ml) and 9.5 ml (8.5-12.5 ml) of net UF in the control and in the C+celecoxib group, respectively. PDF exposure reduced peritoneal performance with a significant fall of net UF volume to 6.1 ml (3.2-8.1 ml) in the PDF group. PD animals undergoing COX-2 inhibition treatment did not lose peritoneal performance and showed a net UF volume of 9.2 ml (8.1-11.9 ml) (PDF versus PDF+celecoxib: P < 0.05; C+celecoxib versus PDF+celecoxib: NS). A glucose absorption test showed 30.2% (26.4-33.7%) absorption in the control group and 30.1% (27.5-32.8%) in the C+celecoxib group (no differences between controls), while PDF-exposed animals had a significant increase in glucose absorption to 48.0% (34.3-57.6%) that was slightly improved in celecoxib-treated animals (42.0%, range 36.2-54.9%, P > 0.05 versus PDF).
Inflammatory markers
No differences between control groups were present either in the cell number or in cell subpopulations (Table 1) . Both PDF-exposed groups had a significantly higher influx of inflammatory cells (with an increase in neutrophils and lymphocytes and a reduction in eosinophils and mast cells) compared to controls. No differences were observed between the PDF and the PDF+celecoxib groups.
Dialysate IL6 was not detectable in any of the four groups. VEGF concentrations did not differ in control groups and increased ∼2-5-fold in both PDF-exposed groups. No differences were present between PDF and PDF+celecoxib animals. The same holds true for MCP-1 and HA: both significantly increased under PDF exposure conditions but no differences were found after celecoxib treatment (Table 1) , although a tendency towards reduced values of MCP-1 and VEGF could be seen in the PDF+ celecoxib group.
Tissue remodelling
Omentum. No differences were observed between the control groups for the mast cell number, blood vessel formation and milky spot response (Table 2 and Figure 1) . In both groups exposed to PDF, a significant increase in these parameters was observed compared to that in the control groups. Animals exposed to PDF and treated with celecoxib had a 2-fold less omentum blood vessel formation (P < 0.01) and an ∼3-fold lower percentage of milky spots surface (P < 0.01) compared to the PDF group. The reduced angiogenesis in the PDF+celecoxib versus the PDF group was associated and positively correlated (r = 0.84) with a significantly lower number of omentum mast cells (P < 0.01) confirming our previous observations [24] . Moreover, a positive correlation was found between the number of blood vessels in omentum and PgE2 levels measured in the PET effluent (r-squared = 0.5083; P = 0.01) of PDF-exposed animals ( Figure 2 ).
Peritoneum. Peritoneum obtained from control animals showed a submesothelial matrix thickness of 10 µm and 9.7 µm in the C and the C+celecoxib groups, respectively ( Figure 3A and B) . This matrix thickness in the peritoneum of PDF animals was significantly increased to 19.6 µm (17.8-27.2 µm) ( Figure 3C ; PDF versus C; P < 0.01). PDF+celecoxib animals showed a lower grade of peritoneal fibrosis with an ECM thickness reduced to 16.3 µm (12.6- Fig. 2 . Correlation between blood vessel number and PgE2 levels. Graph shows positive correlation between omental blood vessels (number/cm 2 ) and PgE2 (pg/ml) levels in dialysates of PDF (black symbols) and PDF+celecoxib (grey symbols) rats (r 2 = 0.54; P = 0.01). Figure 3D ; PDF versus PDF+celecoxib: P < 0.03), although significantly different from control animals (P < 0.01).
µm), (
In control animals, the parietal peritoneum blood vessel number/mm was 4.8 (2.1-9.6) and 4.2 (0.0-5.6) in group C and C+celecoxib, respectively ( Figure 3A and B). After PDF exposure, a dramatic angiogenic response was observed in the PDF group ( Figure 3C ) with an 8-fold increase in blood vessels/mm in comparison to control groups [33.7 (12.5-48.4) P < 0.001]. Concomitant exposure to PDF and celecoxib treatment resulted in drastic attenuation of the angiogenic process resulting in a 40% reduction in the blood vessel number [19.4 (4.0-38.0), P < 0.03; Figure 3D ].
In control animals, 4.4% (0.4-9.9%) of the submesothelial matrix was covered by lymphatic vessels; a small reduction (2.9%) was observed in C+celecoxib animals (1.3-5.3%). In the PDF group, the extension of the lymphatic vessel significantly increased to 12.4% (5.2-19.5% P < 0.03 versus control) that was reduced to normal control values (6.2%) in PDF + celecoxib animals (3.3-10.4%, P > 0.05 versus C, P < 0.03 versus PDF) (Figure 4) .
Staining of parietal peritoneum with an Aqp1 antibody showed an increased intensity of Aqp1 in PDF-treated animals, both at blood vessel and mesothelial cell levels ( Figure 5) . A comparison between the PDF and PDF+ celecoxib groups did not show apparent differences in mesothelial expression of Aqp1, while its expression in vessels was significantly reduced in the PDF+celecoxib group confirming PECAM staining results (see Figure 5) .
VEGF A was increasingly expressed in a cellular expression pattern within the parietal peritoneum of PDFexposed animals in comparison to the control group [5.6% (2.2-9.6%) and 2.9% (8.7-1.0%), respectively, P < 0.05]. Celecoxib treatment induced a non-significant reduction of tissue expression [4.5% (1.5-8.2%) P > 0.05 versus PDF]. The same tendency was observed for VEGF B, expressed in vessels and mesothelial cells, which was increased after PDF exposure [5.6% (2.0-11.2%) P < 0.03 versus control], but slightly reduced after celecoxib [4.8% (0.6-9.0%) P > 0.05% versus PDF].
Mesothelial imprints. Mesothelial cell density (Table 2) was measured as a marker of mesothelial cell regeneration. No differences were present in control animals, while PDF exposure induced a significant increase in mesothelial cell density that celecoxib treatment could not reduce. Spindleshaped cells were found between mesothelial cells in PDFtreated animals. An average of 5.9% (range 4.4-13.8%) of the cells found on the imprints of the PDF group showed this phenotype, whereas these cells were not found in the two control groups (P < 0.01). Celecoxib treatment could not prevent PD-induced induction of these fibroblast-like cells [PDF+celecoxib: 6.0%, (2.0-9.1%), P > 0.05 versus PDF]. 
Discussion
Many clinical and preclinical data suggest a potential role for COX-2 inhibitors in reducing fibrosis and angiogenesis in both in vitro and in vivo settings. In the present study, we investigated the possible modulation of peritoneal fibrosis and angiogenesis related to PDF exposure through celecoxib treatment in a well-described experimental peritoneal dialysis model.
After PDF exposure (4-5 weeks) and celecoxib treatment, fibrosis was clearly reduced in the parietal peritoneum, but more strikingly the angiogenic process (both in omentum and parietal peritoneum) was extremely slower in progression and new lymphatic vessel formation was completely prevented. The improved morphological appearance of the peritoneal membrane resulted in completely preserved membrane UF capacity. Peritoneal inflammatory cell numbers, biomarkers and mesothelial cell regeneration were not affected by celecoxib treatment. Our data are consistent with the hypothesis that COX-2 activity plays a crucial role in the peritoneal membrane fibrotic and (lymph-) angiogenic processes after PDF exposure.
The mechanisms behind the multiple actions of COX inhibitors are very complex, largely redundant and partially unknown as recently reported by Romano et al. [25] . Nevertheless, PgE2 still appears to be a major determinant in most of COX-2-mediated actions. In our study, we focused on the PGE2 and VEGF pathways since many in vitro data reported a correlation between these two molecules and angiogenic processes [5, 6, 8] . As expected, PgE2 was significantly reduced in PET effluents of PDF+celecoxib animals, but was only associated with a slight VEGF reduction in the effluent fluid and at tissue level. This might be explained considering that PgE2 production in inflammatory condition is mainly related to COX-2 activity and hence reduced during celecoxib treatment, while PD-induced VEGF production can be driven by PgE2-independent stimuli. For example, VEGF secretion is upregulated by several growth factors including epidermal and transforming growth factor-α and -β, fibroblast growth factor and platelet-derived growth factor [26, 27] that we cannot exclude from our model of peritoneal exposure. Moreover, prostaglandins can influence angiogenesis by promoting vascular sprouting, migration and tube formation, inducing matrix metalloproteinases synthesis and enhancing endothelial cell survival via Bcl-2 expression and Akt signalling and through many other VEGF-independent mechanisms not investigated in this paper [4] . Coherently, we showed a direct and positive correlation between PgE2 levels and angiogenesis in the omentum of PDF-exposed animals.
Furthermore, it is widely accepted that inflammation is the most relevant process in determining peritoneal membrane deterioration, but in our study we showed a significant better preservation of peritoneal membrane morphology and function even in the absence of a reduced inflammation. In our experiment, no differences were measured both in the mesothelial regeneration process and in the inflammatory cell influx in the peritoneal cavity, and coherently, no differences in MCP1 and HA were found. These findings indicate that the celecoxib-reduced fibrosis and (lymph)angiogenesis are not due to celecoxib-mediated inhibition of inflammation. Recently, a study was published in which PDF-treated mice were subjected to celecoxib treatment [16] . The investigators reported reduction of submesothelial fibrosis, no effects on angiogenesis, along with reduced peritoneal leucocyte numbers upon celecoxib treatment. Based on these observations, the authors concluded that inflammation is an early response to PDF exposure, which in turn leads to fibrosis, whereas angiogenesis does COX-2 inhibition reduces peritoneal worsening after PD 3675 not seem to be entirely dependent on inflammatory reaction. Their results partially disagree with our findings, which might be related to different animal models and variations in the study design. Nevertheless, our finding of a non-antiinflammatory action of the COX-2 inhibitor celecoxib is an important finding, which warrants further exploration. We speculate PGE2 downstream signalling pathways to be major culprits in this respect. On the other hand, several studies indicate that celecoxib can harbour additional pharmacological activities at a micromolecular dose that are completely independent of its COX-2 inhibitory activity. The discovery of additional drug targets [such as protein kinase1 (PDK1) and sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA)] [28] [29] will give new insight into the understanding of celecoxib role in reducing angiogenesis and its potential role in PD setting.
In our study, we measured a completely restored UF capacity after celecoxib treatment. This finding was associated with a slight reduction in glucose absorption probably due to the global reduction in vessel density. The ultrafiltration capacity of the peritoneal membrane is not only influenced by vascular surface area and glucose absorption but also by Aqp1 function, lymphatic absorption rate and submesothelial fibrosis [30, 31] . The role of COX-2 in lymphangiogenesis has been recently investigated in breast cancer where after COX-2 inhibition a decrease of lymphatic vessels has been observed probably due to the effect of PgE2 on VEGF-C production [32] . Accordingly, in our study, we measured a reduction in the number of lymphatic vessels in the parietal peritoneum that can partially explain the higher UF (lower lymphatic reabsorbtion) measured in the celecoxib-treated PD animals. Rippe and Venturoli [31] showed that an increased deposition of collagen fibres in the interstitium appears to be very efficient in reducing UF capacity in a computer-simulated model. Furthermore, in a recent in vitro study, Liu H. et al. [12] demonstrated a positive effect of COX-2 inhibition in reducing the PgE2-mediated ECM production by human mesothelial cells exposed to PDF. Interestingly, in PDF+celecoxib rats, we observed a preserved UF associated with a significantly thinner submesothelial matrix and significantly lower PgE2 levels. Although fibrosis was clearly reduced, no effect of celecoxib treatment was seen on the formation of spindleshaped cells within the mesothelial layer. In an earlier study [33] , we have shown that these spindle-shaped cells likely represent fibroblastic cells as a result of EMT. Our data confirm the findings of Aroeira et al. [16] that celecoxib treatment does not prevent EMT.
The water channel Aqp1 is considered as the ultra small pore of the peritoneal membrane, and its pharmacologic modulation might influence water permeability and improve UF during PD. It has been shown that corticosteroids increase the expression of Aqp1 in the peritoneum with a significant increase in net UF [34] . However, no data are available about possible interactions between COX-2 and Aqp1. In our study, Aqp1 expression was increased after glucose exposure in both PDF groups, but was not influenced by celecoxib treatment, which makes it unlikely that a better UF was due to an increase in Aqp1 channels. Notably, we localized Aqp1 not only in endothelium but also at mesothelial cell level confirming previous in vitro observations from other authors [35] . Collectively, our data thus suggest that improved UF by celecoxib is most likely caused by the reduced vascular surface area, reduced lymphatic absorption and reduced fibrosis.
Major concerns have been raised on cardiovascular safety of COX-2 inhibitors, and the Adenoma Prevention trial with celecoxib has been halted [36] . This condition seems to be common to all COX-2 inhibitor drugs [28] , probably due to a great inhibition of PGI2 (vasodilator and anti-thrombotic prostaglandin) without any effect on platelet production (COX-1 mediated) of the pro-thrombotic prostaglandin thromboxane 2 when administered at high doses. Further studies focussing on the different celecoxib target proteins will provide more specific interventions with, ideally, minimum adverse effects on cardiovascular risk.
In conclusion, our results show that celecoxib treatment reduced peritoneal tissue remodelling after PD exposure and preserved membrane UF capacity. Since celecoxib shows many pleiotropic effects, we could not identify one single mechanism of action in our study, although its antifibrotic and (lymph-)angiostatic properties seem to mediate its relevant effects. In the clinical setting, COX-2 inhibitors showed cardiovascular side effects making them difficult to use. A better comprehension of the molecular mechanisms that regulate COX-2-induced processes is needed to reveal specific targets of intervention that are of clinical interest in preventing PD-related side effects and eventually UF failure.
